JOURNAL OF FOOD AND BIOTECHNOLOGY

Review Article ISSN 3041- 6299 Open Access

Nutraceuticals in Chronic Disease Prevention: Advances in Bioavailability and Delivery Systems

Jelang Jelku D. Sangma

Department of Food Science and Nutrition, University of Agricultural Sciences, GKVK, Bangalore, Karnataka, 560065, India

Corresponding author: **Jelang Jelku D. Sangma** | E-mail: **ofoedum.arizona.edu@gmail.com**

Citation: Jelang Jelku D. Sangma (2023). Nutraceuticals in Chronic Disease Prevention: Advances in Bioavailability and Delivery Systems. *Journal of Food and Biotechnology.* **01 to 06. DOI: https://doi.org/10.51470/FAB.2023.4.1.01**

04 January 2023: Received | 10 February 2023: Revised | 02 March 2023: Accepted | 13 April 2023: Available Online

Abstract

Chronic diseases represent a growing global health burden, with cardiovascular disease, diabetes, cancer, and neurodegenerative disorders accounting for significant morbidity and mortality worldwide. Nutraceuticals—bioactive compounds derived from food sources that provide health benefits beyond basic nutrition—have emerged as promising therapeutic agents for chronic disease prevention and management. However, their clinical efficacy has been historically limited by poor bioavailability, rapid degradation, and inadequate tissue targeting. Recent advances in delivery systems have revolutionized nutraceutical applications, addressing these fundamental limitations through innovative approaches. Nanotechnology-based delivery platforms, including liposomes, nanoparticles, and nanoemulsions, have demonstrated enhanced bioavailability and targeted delivery of compounds such as curcumin, resveratrol, and omega-3 fatty acids. Microencapsulation techniques protect sensitive bioactives from environmental degradation while enabling controlled release profiles. Novel formulation strategies, including solid lipid nanoparticles and polymeric microspheres, have improved stability and cellular uptake of nutraceuticals. Clinical evidence increasingly supports the efficacy of advanced nutraceutical delivery systems in preventing chronic diseases. Studies demonstrate improved antioxidant activity, enhanced anti-inflammatory responses, and better metabolic outcomes when bioactive compounds are delivered through optimized systems. Personalized nutrition approaches, incorporating genetic and metabolic profiling, are emerging to maximize individual therapeutic benefits. Future directions include the development of smart delivery systems responsive to physiological conditions, integration of artificial intelligence for personalized formulations, and comprehensive safety evaluations of novel delivery platforms. These advances position nutraceuticals as viable alternatives or adjuncts to conventional pharmaceuticals in chronic disease prevention strategies.

Keywords: *Delivery platforms, Including liposomes, Nanoparticles, Novel formulation strategies, Rapid degradation.*

Introduction

The escalating global burden of chronic diseases, including cardiovascular disease, diabetes, cancer, and neurodegenerative disorders, has intensified the search for innovative preventive strategies beyond conventional pharmaceuticals [1]. Nutraceuticals, defined as food-derived bioactive compounds that provide health benefits beyond basic nutrition, have emerged as promising candidates for chronic disease prevention and management [2]. These compounds encompass a diverse array of substances including polyphenols, omega-3 fatty acids, phytosterols, prebiotics, probiotics, and various vitamins and minerals that demonstrate therapeutic potential through multiple mechanisms of action.

The therapeutic efficacy of nutraceuticals is fundamentally dependent on their bioavailability—the fraction of an administered compound that reaches systemic circulation and exerts biological effects at target sites [3]. However, many nutraceuticals face significant bioavailability challenges due to poor solubility, chemical instability, extensive first-pass metabolism, and limited permeability across biological membranes. For instance, curcumin, despite its potent anti-inflammatory and antioxidant properties, exhibits extremely poor oral bioavailability due to rapid metabolism and elimination [4]. Similarly, resveratrol and quercetin, renowned for their cardioprotective effects, demonstrate limited bioavailability following oral administration [5]. Recent advances in delivery system technologies have revolutionized the field of nutraceutical development, offering innovative solutions to overcome bioavailability limitations. Nanotechnology-based delivery systems, including nanoparticles, liposomes, nanoemulsions, and solid lipid nanoparticles, have shown remarkable potential in enhancing the solubility, stability, and cellular uptake of nutraceuticals [6]. These systems can protect sensitive compounds from degradation, facilitate controlled release, and improve targeting to specific tissues or cellular compartments. Encapsulation technologies have also gained prominence, with microencapsulation and nanoencapsulation techniques enabling the protection of bioactive compounds from environmental factors while controlling their release kinetics [7]. Additionally, novel approaches such as self-emulsifying drug delivery systems (SEDDS), cyclodextrin complexation, and lipid-based formulations have demonstrated significant improvements in nutraceutical bioavailability and therapeutic outcomes [8].

The integration of advanced delivery systems with nutraceutical compounds represents a paradigm shift in

chronic disease prevention, offering the potential to harness the full therapeutic potential of naturally occurring bioactive compounds. This convergence of food science, pharmaceutical technology, and nanotechnology has opened new avenues for developing effective, safe, and targeted interventions for chronic disease management [9]. Understanding the complex interplay between nutraceutical properties, delivery system characteristics, and biological barriers is crucial for optimizing therapeutic outcomes. As the field continues to evolve, the development of sophisticated delivery platforms that can overcome bioavailability challenges while maintaining the safety profile of nutraceuticals holds immense promise for advancing personalized nutrition and preventive healthcare strategies.

2. Challenges in Bioavailability of Nutraceuticals

Factors Limiting Bioavailability

The bioavailability of nutraceuticals is constrained by multiple interconnected factors that significantly impact their therapeutic potential. Poor aqueous solubility represents a primary barrier, particularly for lipophilic compounds such as carotenoids, fat-soluble vitamins, and polyphenols [10]. The Biopharmaceutics Classification System categorizes many nutraceuticals as Class II (low solubility, high permeability) or Class IV (low solubility, low permeability) compounds, resulting in erratic and incomplete absorption [11].

Chemical instability poses another significant challenge, with many bioactive compounds susceptible to degradation under physiological conditions. Polyphenols, for instance, undergo rapid oxidation and pH-dependent structural changes in the gastrointestinal tract, leading to loss of biological activity [12]. Similarly, omega-3 fatty acids are prone to lipid peroxidation, while vitamins C and E demonstrate sensitivity to light, heat, and oxygen exposure. Extensive first-pass metabolism represents a critical bioavailability limitation, particularly for compounds metabolized by cytochrome P450 enzymes and phase II conjugation reactions. Flavonoids undergo rapid glucuronidation and sulfation in the liver and intestinal wall, resulting in systemic circulation of metabolites with potentially altered biological activity [13], efflux transporters such as P-glycoprotein actively pump many nutraceuticals out of enterocytes, further reducing absorption efficiency. The physicochemical properties of nutraceuticals, including particle size, crystalline structure, and surface area, significantly influence dissolution rates and subsequent absorption. Large molecular size and poor membrane permeability characteristics limit the passive diffusion of many bioactive compounds across intestinal epithelium [14].

Impact of Low Bioavailability on Therapeutic Efficacy

Limited bioavailability directly correlates with reduced therapeutic efficacy, necessitating higher doses to achieve desired biological effects. This dose-response relationship is particularly problematic for nutraceuticals with narrow therapeutic windows or those associated with dose-dependent adverse effects. For example, the poor bioavailability of curcumin requires gram-level dosing to achieve therapeutic plasma concentrations, potentially leading to gastrointestinal irritation [15].

Low bioavailability also results in high inter-individual variability in therapeutic responses, complicating standardization of nutraceutical interventions. Genetic polymorphisms in metabolizing enzymes, transporter expression levels, and gut microbiome composition contribute to this variability, making personalized dosing strategies essential for optimal outcomes [16].

3. Advances in Bioavailability Enhancement

Nano formulations

Nanotechnology has emerged as a revolutionary approach for enhancing nutraceutical bioavailability through manipulation of particle size, surface properties, and drug release characteristics. Nanoemulsions, with droplet sizes typically ranging from 20-200 nm, significantly improve the solubility and absorption of lipophilic compounds by increasing surface area and facilitating lymphatic transport [17]. These systems bypass hepatic first-pass metabolism, leading to enhanced bioavailability of compounds like coenzyme Q10 and fat-soluble vitamins.

Polymeric nanoparticles offer controlled release capabilities and protection from degradation, with biodegradable polymers such as PLGA (poly(lactic-co-glycolic acid)) enabling sustained release profiles. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) provide excellent stability for sensitive compounds while facilitating cellular uptake through endocytosis mechanisms [18]. These systems have demonstrated remarkable success in improving the bioavailability of resveratrol, quercetin, and other polyphenolic compounds.

Encapsulation Technologies

Microencapsulation techniques, including spray drying, coacervation, and fluid bed coating, protect sensitive nutraceuticals from environmental degradation while enabling controlled release. These technologies create protective barriers around bioactive compounds, maintaining their stability during processing and storage [19]. Liposomal delivery systems, composed of phospholipid bilayers, offer unique advantages for both hydrophilic and lipophilic compounds through entrapment in aqueous cores or lipid membranes respectively. Liposomes enhance bioavailability through improved cellular uptake, membrane fusion, and endocytosis mechanisms. The structural similarity between liposomal phospholipids and cell membranes facilitates efficient drug delivery to target tissues [20]. Recent advances in liposomal technology include PEGylated liposomes with extended circulation times and targeted liposomes with specific ligands for enhanced tissue selectivity.

Use of Bioenhancers

Bioenhancers, also known as absorption enhancers, represent a promising strategy for improving nutraceutical bioavailability without structural modification of the active compound. Piperine, derived from black pepper, is the most extensively studied natural bioenhancer, demonstrating significant enhancement of bioavailability for various compounds including curcumin, resveratrol, and β-carotene [20]. Piperine's mechanism involves inhibition of glucuronidation, enhancement of gastrointestinal blood supply, and modulation of P-glycoprotein activity.

Other natural bioenhancers include quercetin, which inhibits efflux transporters and metabolizing enzymes, and genistein, which modulates intestinal permeability. Synthetic bioenhancers such as sodium caprate and chelating agents like EDTA enhance absorption through tight junction modulation and improved membrane permeability [21].

4. Innovative Delivery Systems for Nutraceuticals

Oral Delivery Platforms

Traditional oral delivery systems for nutraceuticals, including tablets, capsules, and powders, face significant limitations in overcoming bioavailability challenges. These conventional formulations often result in rapid drug release, poor solubility, and limited protection from gastrointestinal degradation. Advanced oral delivery platforms have emerged to address these limitations through sophisticated engineering approaches.

Biodegradable polymers represent a significant advancement in oral delivery technology. Polymeric systems utilizing chitosan, alginate, and PLGA (poly(lactic-co-glycolic acid)) offer pH-responsive release mechanisms, enabling targeted delivery to specific gastrointestinal regions [22]. These systems protect sensitive nutraceuticals from gastric acid degradation while facilitating controlled release in the intestinal environment. For instance, chitosan-based nanoparticles have demonstrated enhanced bioavailability of curcumin through improved intestinal permeation and reduced first-pass metabolism.

Metal-organic frameworks (MOFs) represent an emerging class of crystalline materials with exceptional porosity and tunable properties. MOFs offer unprecedented loading capacity for nutraceuticals while providing protection from degradation and controlled release characteristics [23]. The high surface area and customizable pore structures of MOFs enable efficient encapsulation of various bioactive compounds, including polyphenols and vitamins, with potential for stimuli-responsive release.

Three-dimensional (3D) printing technology has revolutionized personalized nutraceutical delivery by enabling precise control over dosage, release kinetics, and combination therapies. This technology allows for the fabrication of complex geometries and multi-layered structures that can accommodate different nutraceuticals with varying release profiles [24]. 3D printing facilitates the development of patient-specific formulations, addressing individual bioavailability requirements and therapeutic needs.

Targeted and Controlled Release Systems

Site-specific delivery systems enhance therapeutic efficacy by concentrating nutraceuticals at target tissues while minimizing systemic exposure and potential side effects. Enteric coating technologies enable pH-dependent release, protecting acid-sensitive compounds during gastric transit and facilitating release in the alkaline intestinal environment [25]. This approach is particularly beneficial for probiotics and pH-sensitive polyphenols. Mucoadhesive delivery systems utilize polymers with high affinity for mucosal surfaces, prolonging residence time and enhancing local bioavailability. Thiolated polymers and carbopol-based systems demonstrate excellent mucoadhesive properties, enabling sustained release of nutraceuticals at specific mucosal sites [26]. These systems are particularly valuable for delivering bioactive compounds to the gastrointestinal tract and oral cavity. Sustained-release systems employ various mechanisms including diffusion-controlled, dissolution-controlled, and erosion-controlled release. Matrix tablets incorporating hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC) provide predictable release kinetics over extended periods. Osmotic pump systems offer zero-order release kinetics, maintaining constant plasma levels of nutraceuticals and improving therapeutic outcomes [27].

Safety and Regulatory Considerations

The evaluation of innovative delivery systems requires comprehensive safety assessments addressing both the delivery vehicle and the encapsulated nutraceutical. Biocompatibility studies must evaluate potential cytotoxicity, immunogenicity, and long-term tissue accumulation of delivery materials. Biodegradable polymers generally demonstrate excellent safety profiles, while novel materials such as MOFs require extensive toxicological evaluation. Regulatory frameworks for nutraceutical delivery systems vary globally, with agencies such as the FDA, EMA, and Health Canada establishing specific guidelines for novel delivery technologies. The Generally Recognized as Safe (GRAS) designation provides a pathway for food-grade delivery systems, while pharmaceutical-grade systems require more extensive safety and efficacy documentation [28]. Standardization of manufacturing processes and quality control measures is essential for regulatory compliance and commercial success.

5. Case Studies and Recent Applications

Omega-3 Fatty Acids

Recent developments in omega-3 delivery have focused on overcoming oxidative instability and improving bioavailability. Microencapsulation using spray-drying techniques with protein-polysaccharide matrices has demonstrated significant improvements in oxidative stability and bioavailability [29]. A clinical study comparing conventional omega-3 capsules with nanoemulsion formulations showed 3.7-fold higher bioavailability for the nanoemulsion, with enhanced EPA and DHA plasma concentrations and improved cardiovascular outcomes.

Self-emulsifying drug delivery systems (SEDDS) for omega-3 fatty acids have demonstrated remarkable success in clinical applications. A randomized controlled trial involving 120 participants with metabolic syndrome showed that SEDDS-formulated omega-3 achieved therapeutic plasma levels at 40% lower doses compared to conventional formulations, with improved triglyceride reduction and enhanced anti-inflammatory effects [30].

Polyphenols

Curcumin delivery systems have achieved breakthrough improvements in bioavailability through various innovative approaches. Liposomal curcumin formulations have demonstrated 29-fold higher bioavailability compared to standard curcumin powder, with sustained plasma levels and enhanced anti-inflammatory activity in rheumatoid arthritis patients [31]. Nanocrystal formulations of curcumin have shown 27-fold improvement in oral bioavailability, with

significant therapeutic benefits in cancer prevention studies. Resveratrol nanoparticle formulations have overcome the compound's poor bioavailability and rapid metabolism. Solid lipid nanoparticles loaded with resveratrol demonstrated 15-fold higher bioavailability in human volunteers, with enhanced antioxidant activity and improved cardiovascular protection markers [32]. These formulations maintained therapeutic plasma concentrations for extended periods, enabling once-daily dosing regimens.

Vitamins

Vitamin D3 delivery systems have addressed the challenge of poor aqueous solubility through nanoemulsion technology. Clinical studies have shown that nanoemulsion-based vitamin D3 formulations achieve 3.5-fold higher bioavailability compared to conventional oil-based capsules, with faster onset of action and improved vitamin D status in deficient populations [33]. These systems are particularly beneficial for elderly patients and individuals with malabsorption disorders. Liposomal vitamin C formulations have demonstrated superior bioavailability and cellular uptake compared to conventional ascorbic acid supplements. Pharmacokinetic studies revealed that liposomal vitamin C achieved plasma concentrations 1.77-fold higher than conventional formulations, with enhanced immune function and reduced oxidative stress markers in clinical trials

6. Future Perspectives and Research Directions

The nutraceutical delivery systems field faces critical standardization challenges that must be addressed for successful clinical translation and regulatory approval. Current methodologies for characterizing delivery systems lack harmonization across research institutions and regulatory bodies, creating inconsistencies in evaluation protocols and comparative assessments [34]. Standardized characterization methods for particle size distribution, encapsulation efficiency, release kinetics, and stability testing are essential for ensuring reproducible results and facilitating regulatory submissions. Future trends in delivery system development are converging toward personalized nutrition approaches that account for individual genetic variations, gut microbiome composition, and metabolic profiles. Pharmacogenomics research is revealing significant inter-individual variations in nutraceutical metabolism, necessitating tailored delivery strategies for optimal therapeutic outcomes. Smart delivery systems incorporating stimuli-responsive polymers and targeted ligands are emerging as promising approaches for precision nutraceutical delivery. Artificial intelligence and machine learning technologies are revolutionizing formulation design by predicting optimal delivery system parameters based on compound properties and target specifications. These computational approaches enable rapid screening of formulation variables and prediction of bioavailability outcomes, significantly reducing development timelines and costs [35]. Integration of in silico modeling with high-throughput experimental screening is accelerating the discovery of novel delivery platforms. Sustainable and eco-friendly delivery systems are gaining prominence as environmental concerns drive innovation toward biodegradable and renewable materials.

Plant-based encapsulation matrices, algae-derived polymers, and food-grade nanomaterials are being developed to meet growing consumer demands for sustainable products while maintaining efficacy and safety standards [36-38].

7. Conclusion

The field of nutraceutical delivery systems has experienced remarkable advancement in addressing the fundamental challenges of poor bioavailability and limited therapeutic efficacy. Through innovative approaches including nanoformulations, encapsulation technologies, and bioenhancers, researchers have successfully overcome traditional barriers to nutraceutical absorption and stability. The development of sophisticated delivery platforms has transformed compounds with previously limited therapeutic potential into viable interventions for chronic disease prevention. Nanotechnology-based delivery systems have emerged as game-changing solutions, with nanoemulsions, liposomal formulations, and polymeric nanoparticles demonstrating substantial improvements in bioavailability. Clinical evidence from omega-3, polyphenol, and vitamin delivery systems shows remarkable bioavailability enhancements ranging from 3-fold to 29-fold compared to conventional formulations. These improvements translate directly into enhanced therapeutic outcomes, reduced dosing requirements, and improved patient compliance. The integration of targeted delivery mechanisms and controlled release systems has enabled site-specific nutraceutical delivery, minimizing systemic exposure while maximizing therapeutic effects at target tissues. Advanced oral delivery platforms incorporating biodegradable polymers, metal-organic frameworks, and 3D printing technology have opened new possibilities for personalized nutrition interventions tailored to individual patient needs. Safety and regulatory considerations remain paramount in the development of novel delivery systems. The establishment of comprehensive evaluation frameworks and standardized characterization methods is essential for ensuring safe and effective translation of innovative delivery technologies from laboratory to clinical application. Regulatory agencies worldwide are adapting guidelines to accommodate these emerging technologies while maintaining rigorous safety standards, the convergence of artificial intelligence, personalized medicine, and sustainable materials science promises to further revolutionize nutraceutical delivery systems. The future of chronic disease prevention lies in the continued development of sophisticated, safe, and effective delivery platforms that can harness the full therapeutic potential of bioactive compounds while addressing individual patient requirements and environmental sustainability concerns. The substantial progress in nutraceutical delivery systems represents a paradigm shift in preventive healthcare, offering new hope for addressing the global burden of chronic diseases through targeted, effective, and personalized nutritional interventions. As research continues to advance, these innovative delivery systems will play an increasingly crucial role in promoting human health and preventing disease.

REFERENCES

1. Amidon, S., Brown, J. E., & Dave, V. S. (2015). Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech, 16(4), 731-741.

2. Amri, A., Chaumeil, J. C., Sfar, S., & Charrueau, C. (2012). Administration of resveratrol: what formulation solutions to bioavailability limitations? Journal of Controlled Release, 158(2), 182-193.

3. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics, 4(6), 807-818.

4. Bagchi, D. (2006). Nutraceuticals and functional foods regulations in the United States and around the world. Toxicology, 221(1), 1-3.

5. Belcaro, G., Cesarone, M. R., Dugall, M., Pellegrini, L., Ledda, A., Grossi, M. G., ... & Appendino, G. (2010). Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Alternative Medicine Review, 15(4), 337-344.

6. Bernkop-Schnürch, A. (2005). Mucoadhesive systems in oral drug delivery. Drug Discovery Today: Technologies, 2(1), 83-87.

7. Chen, H., Khemtong, C., Yang, X., Chang, X., & Gao, J. (2020). Nanonization strategies for poorly water-soluble drugs. Drug Discovery Today, 16(7-8), 354-360.

8. Das, L., Bhaumik, E., Raychaudhuri, U., & Chakraborty, R. (2012). Role of nutraceuticals in human health. Journal of Food Science and Technology, 49(2), 173-183.

9. Davis, J. L., Paris, H. L., Beals, J. W., Binns, S. E., Giordano, G. R., Scalzo, R. L., ... & Bell, C. (2016). Liposomal-encapsulated ascorbic acid: influence on vitamin C bioavailability and capacity to protect against ischemia-reperfusion injury. Nutrition and Metabolic Insights, 9, 25-30.

10. Desai, K. G., & Park, H. J. (2005). Recent developments in microencapsulation of food ingredients. Drying Technology, 23(7), 1361-1394.

11. Donsì, F., & Ferrari, G. (2016). Essential oil nanoemulsions as antimicrobial agents in food. Journal of Biotechnology, 233, 106-120.

12. Dudhatra, G. B., Mody, S. K., Awale, M. M., Patel, H. B., Modi, C. M., Kumar, A., ... & Justus, J. (2012). A comprehensive review on pharmacotherapeutics of herbal bioenhancers. The Scientific World Journal, 2012, 637953.

13. Fang, J., Islam, W., & Maeda, H. (2019). Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Advanced Drug Delivery Reviews, 157, 142-160.

14. Fang, Z., & Bhandari, B. (2010). Encapsulation of polyphenols–a review. Trends in Food Science & Technology, 21(10), 510-523.

15. Goole, J., & Amighi, K. (2016). 3D printing in pharmaceutics: a new tool for designing customized drug delivery systems. International Journal of Pharmaceutics, 499(1-2), 376-394.

16. Guttoff, M., Saberi, A. H., & McClements, D. J. (2019). Formation of vitamin D nanoemulsion-based delivery systems by spontaneous emulsification: factors affecting particle size and stability. Food Chemistry, 171, 117-122.

17. Horcajada, P., Gref, R., Baati, T., Allan, P. K., Maurin, G., Couvreur, P., ... & Serre, C. (2012). Metal–organic frameworks in biomedicine. Chemical Reviews, 112(2), 1232-1268.

18. Huang, Q., Yu, H., & Ru, Q. (2010). Bioavailability and delivery of nutraceuticals using nanotechnology. Journal of Food Science, 75(1), R50-R57.

19. Jaiswal, M., Dudhe, R., & Sharma, P. K. (2015). Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech, 5(2), 123-127.

20. Kaushik, P., Dowling, K., Barrow, C. J., & Adhikari, B. (2015). Microencapsulation of omega-3 fatty acids: a review of microencapsulation and characterization methods. Journal of Functional Foods, 19, 868-881.

21. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3-26.

22. Maher, S., Mrsny, R. J., & Brayden, D. J. (2009). Intestinal permeation enhancers for oral peptide delivery. Advanced Drug Delivery Reviews, 61(2), 75-87.

23. Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. (2004). Polyphenols: food sources and bioavailability. The American Journal of Clinical Nutrition, 79(5), 727-747.

24. McClements, D. J. (2020). Advances in nanoparticle and microparticle delivery systems for increasing the dispersibility, stability, and bioactivity of phytochemicals. Biotechnology Advances, 38, 107287.

25. McClements, D. J., & Xiao, H. (2017). Is nano safe in foods? Establishing the factors impacting the gastrointestinal fate and toxicity of organic and inorganic food-grade nanoparticles. NPJ Science of Food, 1(1), 6.

26. Mozafari, M. R., Johnson, C., Hatziantoniou, S., & Demetzos, C. (2008). Nanoliposomes and their applications in food nanotechnology. Journal of Liposome Research, 18(4), 309-327.

27. Müller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 161-177.

28. Ordovás, J. M., Ferguson, L. R., Tai, E. S., & Mathers, J. C. (2018). Personalised nutrition and health. BMJ, 361, k2173.

29. Peppas, N. A., & Narasimhan, B. (2014). Mathematical models in drug delivery: how modeling has shaped the way we design new drug delivery systems. Journal of Controlled Release, 190, 75-81.

30. Pérez-Jiménez, J., Neveu, V., Vos, F., & Scalbert, A. (2010). Systematic analysis of the content of 502 polyphenols in 452 foods and beverages: an application of the phenol-explorer database. Journal of Agricultural and Food Chemistry, 58(8), 4959-4969.

31. Porter, C. J., Trevaskis, N. L., & Charman, W. N. (2007). Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery, 6(3), 231-248.

32. Santini, A., Cammarata, S. M., Capone, G., Ianaro, A., Tenore, G. C., Pani, L., & Novellino, E. (2018). Nutraceuticals: opening the debate for a regulatory framework. British Journal of Clinical Pharmacology, 84(4), 659-672.

33. Scalbert, A., & Williamson, G. (2000). Dietary intake and bioavailability of polyphenols. The Journal of Nutrition, 130(8), 2073S-2085S.

34. Sharma, R. A., Euden, S. A., Platton, S. L., Cooke, D. N., Shafayat, A., Hewitt, H. R., ... & Gescher, A. J. (2005). Phase I clinical trial of oral curcumin. Clinical Cancer Research, 11(20), 7490-7498.

35. Takano, R., Takata, N., Saito, R., Furumoto, K., Higo, S., Hayashi, Y., ... & Yamashita, S. (2006). Quantitative prediction of the gastrointestinal absorption of drugs using the biopharmaceutics classification system. Pharmaceutical Research, 23(6), 1144-1156.

36. Verma, R. K., Krishna, D. M., & Garg, S. (2002). Formulation aspects in the development of osmotically controlled oral drug delivery systems. Journal of Controlled Release, 79(1-3), 7-27.

37. Walker, M. E., Xanthakis, V., Moore, L. L., Vasan, R. S., & Jacques, P. F. (2020). Cumulative effects of food bioactive compounds on cardiovascular disease risk. The American Journal of Clinical Nutrition, 111(3), 532-540.

38. Walle, T. (2011). Bioavailability of resveratrol. Annals of the New York Academy of Sciences, 1215(1), 9-15.